NCT Number: NCT05501548
Phase: PHASE2
Trial Summary: This is a study to evaluate the safety and clinical activity of the combination of olaparib and high-dose IV ascorbate, as second or later line of therapy, in castration resistant prostate cancer pati – clinicaltrials.gov for more information and locations
Clinicaltrials.gov
Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acronym:
Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives